# US 2021/0299218 A1 · Neuroprotective compositions and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0299218 A1
- Document ID: US20210299218A1
- Status: Published application
- Kind: A1
- Application number: 17/265,158
- Filed: 2019-08-01
- Published: 2021-09-30
- Earliest claimed: 2018-08-01
- Assignees: NanoNeuron Therapeutics, Inc.
- Applicants: NanoNeuron Therapeutics, Inc.
- Inventors: Qiang Feng; Gina Elsen; Po-Hsuen Chen; Shi-Jiang Lu
- Web page: https://patentgrep.com/patent/US20210299218A1

## CPC

- A61K 38/1709: {from mammals}
- A61K 38/185: {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}
- A61K 9/5138: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 38/204: {IL-6}
- A61K 38/2093: {Leukaemia inhibitory factor [LIF]}
- A61K 38/212: {IFN-alpha}
- A61K 38/215: {IFN-beta}
- A61K 38/217: {IFN-gamma}
- A61K 38/2257: {Prolactin}
- A61K 38/2264: {Obesity-gene products, e.g. leptin}
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates generally to biocompatible nanoparticles, and in particular, neuroprotective nanoparticles comprising ciliary neurotrophic factor and/or oncostatin M. Methods for making and using the same are also provided.

## Claims

### Claim 1

A composition for use in the treatment of a disease or condition in a subject in need thereof, comprising:
a plurality of nanoparticles comprising dextran sulfate and chitosan; and
an effective amount of a neurotrophic factor associated with the nanoparticles, wherein the neurotrophic factor is selected from the group consisting of Brain-derived neurotrophic factor (BDNF), Nerve growth factor (NGF), Neurotrophin-3 (NT-3), Neurotrophin-4 (NT-4), Ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), interleukin-6 (IL-6), prolactin, growth hormone, leptin, interferons (i.e., interferon-α, -β, and -γ), oncostatin M (OSM), Glial cell line-derived neurotrophic factor (GDNF), Artemin, Neurturin, Persephin, and Ephrins.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the nanoparticles have an average diameter of about 200 nm to about 800 nm.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the nanoparticles have an average diameter of about 200 nm to about 500 nm.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the dextran sulfate and chitosan are present in a weight ratio of about 10:1 to about 1:10, or about 5:1 to about 1:1.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the dextran sulfate and chitosan are present in a weight ratio of about 4:1.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the neurotrophic factor is incorporated into the nanoparticles.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the neurotrophic factor is recombinantly produced.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the neurotrophic factor is CNTF and/or OSM.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the neurotrophic factor is CNTF.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the neurotrophic factor is OSM.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the nanoparticles provide sustained and/or prolonged delivery of the neurotrophic factor.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the sustained and/or prolonged delivery comprises delivery for at least 6 hours, at least 12 hours, at least 24 hours, at least 48 hours.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the disease or condition is a neurodegenerative disease.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the disease or condition is a retinal neurodegeneration disease.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the retinal neurodegeneration disease is retinal degeneration and/or dystrophy (such as Leber congenital amaurosis, retinitis pigmentosa, cone-rod dystrophy, microphthalmia, anophthalmia, myopia, and hyperopia) or retinal neuronal death related diseases (such as glaucoma and age related macular degeneration, diabetic retinopathy, retinal blood vessel occlusions, retinal medication toxicity (such as what amino glycosides or plaquenil can cause), retinal trauma (e.g., post-surgical), retinal infections, choroidal dystrophies, retinal pigmentary retinopathies, inflammatory and cancer mediated auto immune diseases that result in retinal neuronal cell death).